

Resource Summary Report

Generated by PRECISE-TBI on Sep 20, 2026

NOD.Cg-Prkdc^{scid} Il2rg/SzJ

RRID:IMSR_JAX:005557

Type: Organism

Proper Citation

RRID:IMSR_JAX:005557

Organism Information

URL: <https://www.jax.org/strain/005557>

Proper Citation: RRID:IMSR_JAX:005557

Description: Mus musculus with name NOD.Cg-Prkdc^{scid} Il2rg/SzJ from IMSR.

Species: Mus musculus

Synonyms: NOD-scid IL2Rg. NSG. NOD scid gamma. NOD-scid IL2Rgamma

Notes: gene symbol note: protein kinase; DNA activated; catalytic polypeptide|interleukin 2 receptor; gamma chain; mutant strain|congenic strain: Prkdc|Il2rg

Affected Gene: protein kinase; DNA activated; catalytic polypeptide|interleukin 2 receptor; gamma chain

Genomic Alteration: severe combined immunodeficiency|targeted mutation 1; Warren J Leonard

Catalog Number: JAX:005557

Database: JAX Mice and Services

Database Abbreviation: JAX

Availability: live

Organism Name: NOD.Cg-Prkdc^{scid} Il2rg/SzJ

Record Creation Time: 20250513T053650+0000

Record Last Update: 20260919T054840+0000

Ratings and Alerts

- Used for genotyping by the Human Islet Research Network community. Contact(s): Seung Kim, Simona Chera, Pedro Herrera, Charles Chang - Human Islets Research Network <https://hirnetwork.org/>

No alerts have been found for NOD.Cg-Prkdc^{scid} Il2rg/SzJ.

Data and Source Information

Source: [Integrated Animals](#)

Source Database: JAX Mice and Services

Usage and Citation Metrics

We found 1054 mentions in open access literature.

Listed below are recent publications. The full list is available at [PRECISE-TBI](#) .

Stoiber S, et al. (2026) [18F]FDG PET/CT multiomics identifies Hedgehog-driven HPV-negative head and neck squamous cell carcinoma. *Molecular cancer*, 25(1).

Kishimoto S, et al. (2026) Band-Selective IR PRESS for Brain Tumor Spectroscopy Allows Robust Detection of Lactate. *NMR in biomedicine*, 39(3), e70220.

Peterson NC, et al. (2026) Development of a Plasma Spot Assay for Detection of Fluorophore-labeled Antibodies in Mouse Imaging Studies. *In vivo (Athens, Greece)*, 40(4), 1904.

Çak?lkaya P, et al. (2026) Targeting uPARAP with an Antibody-Drug Conjugate Exhibits Efficacy against Mesothelioma and Synergizes with Cisplatin. *Cancer research communications*, 6(1), 130.

Mansell RP, et al. (2026) Ether lipids influence cancer cell fate by modulating iron uptake. *Nature communications*, 17(1), 1835.

Berry BC, et al. (2026) Epigenetic buffering of proteotoxic stress by EHMT2 enables meningioma growth. *Neuro-oncology advances*, 8(1), vdag037.

Chung IC, et al. (2026) Extracellular Enolase-1 Promotes CAF-Associated Stromal Reprogramming via the Plasmin/TGF-? Axis in Multiple Myeloma. *Cancers*, 18(9).

Wang JG, et al. (2026) The long noncoding RNA Inc-FAM164A1-ACLY axis promotes pro-inflammatory responses in human primary macrophages: a systems approach. *Frontiers in immunology*, 17, 1776849.

Feng Z, et al. (2026) Engineered VPg saRNA achieves cap-independent, low-immunogenic and precise encoding of therapeutic proteins in vivo. *Nature communications*, 17(1), 1666.

Wagner KK, et al. (2026) Xenograft tissue slice tandem co-cultures are a highly specific model to selectively analyze drug inhibitory effects on glioblastoma invasion. *The Journal of biological chemistry*, 302(1), 110986.

Barajas JM, et al. (2026) Tandem Duplications in UBTF Create XPO1-Dependent Nuclear Export Signals that Reveal a Leukemic Therapeutic Dependency. *Blood cancer discovery*, 7(1), 51.

Kehm H, et al. (2026) Dissection of the T cell infiltrate in mouse pancreatic tumors reveals an extensive and diverse tumor-reactive T cell repertoire. *Science advances*, 12(15), eadr6132.

López-Fuentes E, et al. (2026) Epigenetic and Transcriptional Programs Define Osteosarcoma Subtypes and Establish Targetable Vulnerabilities. *Cancer discovery*, 16(2), 296.

García-Vicente R, et al. (2026) The Potential of the Gut Microbiota and Butyrate to Enhance CAR T-cell Therapy in Non-Hodgkin Lymphoma. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 32(2), 375.

Shinder BM, et al. (2026) Targeting Tumor Microenvironment-Derived NRG1-HER2/3 Signaling with Zenocutuzumab Restores Sensitivity to AR Inhibition in PTEN Wild-type Prostate Cancer. *Molecular cancer therapeutics*, 25(4), 662.

Mari A, et al. (2026) ATAD2 drives melanoma growth and progression and inhibits ferroptosis. *EMBO reports*, 27(2), 501.

Kim M, et al. (2026) Bone Metastatic Progression of Prostate Cancer Is Regulated by TRIM28-LDHA-Mediated Metabolism. *Molecular cancer research : MCR*, 24(2), 93.

Yang J, et al. (2026) GLS1 Orchestrates Exosome-Mediated Tumor-Endothelial Communication to Facilitate Angiogenesis. *Advanced science (Weinheim, Baden-Wurttemberg, Germany)*, 13(41), e75510.

Zhang X, et al. (2026) Human pancreatic progenitor organoids define genetic and epigenetic barriers to early PDAC transformation. *Developmental cell*, 61(6), 1190.

Gumpert N, et al. (2026) Recurrent Immunogenic Neoantigens and Their Cognate T-cell Receptors in Treatment-Resistant Metastatic Prostate Cancer. *Cancer discovery*, 16(2), 250.